




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Influenza is more common than Middle East Respiratory Syndrome Coronavirus (MERS-CoV) among hospitalized adult Saudi patients

Jaffar A. Al-Tawfiq^{a,b,*}, Ali A. Rabaan^c, Kareem Hinedi^d

^a Specialty Internal Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia

^b Indiana University School of Medicine, Indianapolis, IN, USA

^c Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia

^d Division of Hospital Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia

ARTICLE INFO

Keywords:

MERS-CoV

Surveillance

Middle east respiratory syndrome coronavirus

Influenza

Community acquired pneumonia

CAP

ABSTRACT

Background: Since the initial description of Middle East Respiratory Syndrome Coronavirus (MERS-CoV), we adopted a systematic process of screening patients admitted with community acquired pneumonia. Here, we report the result of the surveillance activity in a general hospital in Saudi Arabia over a four year period.

Materials and methods: All admitted patients with community acquired pneumonia from 2012 to 2016 were tested for MERS-CoV. In addition, testing for influenza viruses was carried out starting April 2015.

Results: During the study period, a total of 2657 patients were screened for MERS-CoV and only 20 (0.74%) tested positive. From January 2015 to December 2016, a total of 1644 patients were tested for both MERS-CoV and influenza. None of the patients tested positive for MERS-CoV and 271 (16.4%) were positive for influenza. The detected influenza viruses were Influenza A (107, 6.5%), pandemic 2009 H1N1 (n = 120, 7.3%), and Influenza B (n = 44, 2.7%). Pandemic H1N1 was the most common influenza in 2015 with a peak in peaked October to December and influenza A other than H1N1 was more common in 2016 with a peak in August and then October to December.

Conclusions: MERS-CoV was a rare cause of community acquired pneumonia and other viral causes including influenza were much more common. Thus, admitted patients are potentially manageable with Oseltamivir or Zanamivir therapy.

1. Introduction

The emergence of the Middle East respiratory Syndrome Coronavirus (MERS-CoV) in September 2012 had attracted international attention. The virus was initially isolated from a patient with a fatal community acquired pneumonia (CAP) in Saudi Arabia [1]. Since then, multiple hospital outbreaks occurred within [2–7] and outside Saudi Arabia [8–11]. As of May 1st, 2017, the World Health Organization reported 1952 laboratory-confirmed cases worldwide and at least 693 related deaths [12]. A wide-spectrum of MERS-CoV infection was described and ranges from mild to severe and fulminant infections leading to severe acute respiratory disease [2,13–15]. In the Kingdom of Saudi Arabia, the number of MERS-CoV cases was 1601 as of May 6th, 2017 [16]. Since most of the cases of MERS-CoV in Saudi Arabia occurred due to intra- and inter-hospital transmissions, there was an increased amplification of the transmission [2–4,9–11,17]. Early detection and isolation of patients with MERS-CoV infection remains an important factor for the control of MERS-CoV transmission [18,19].

One of the goals of the surveillance of emerging respiratory viruses is the rapid and early identification and placement of control measures [20]. Following the initial description of the disease [1], the ministry of health in the Kingdom of Saudi Arabia put in place a surveillance and screening program for patients admitted with respiratory illness [21]. Similarly, we adopted universal screening of admitted patients with community acquired pneumonia. Here, we report the result of the surveillance activity in a general hospital in Saudi Arabia over a four year period.

2. Materials and methods

The study was conducted at a 350-bed general hospital, which also accepts referred patients. The hospital provides medical care for about 160,000 individuals eligible for medical care. The hospital has 5 intensive care units (cardiac, medical, surgical, pediatric, and neonatal) [22]. All admitted patients with community acquired pneumonia from 2012 to 2016 were tested for MERS-CoV. The case definition of

* Corresponding author. P.O. Box 76, Room A-428-2, Building 61, Dhahran Health Center, Saudi Aramco, Dhahran 31311, Saudi Arabia.
E-mail addresses: jaffar.tawfiq@jhah.com, jaltawfi@yahoo.com (J.A. Al-Tawfiq).

suspected MERS-CoV was an acute febrile respiratory illness (fever, cough, or dyspnea) with radiographic evidence of pneumonia [22]. We collected data for all suspected patients using a standard Microsoft Excel data collection sheet. Both electronic and paper medical records were reviewed. We recorded the age and the date of admission and the MERS-CoV and influenza results. The study was approved by the Johns Hopkins Aramco Healthcare Institutional Review Board (IRB).

2.1. MERS-CoV and influenza testing

Suspected patients had either Dacron-flocked nasopharyngeal swabs, or sputum testing for MERS-CoV. The testing was done at the Saudi Ministry of Health MERS-CoV laboratory and at the main hospital. Clinical samples were screened with real-time reverse-transcriptase (RT)–PCR as described previously [23]. The test amplified both the upstream E protein (upE gene) and ORF1a for MERS-CoV and if both assays were positive then the diagnosis of MERS-CoV was made, as described previously [14]. The influenza test was carried out at the Johns Hopkins Aramco Healthcare Centre, Dhahran, using the Cepheid® Xpert Flu assay multiplex real-time PCR. The tested influenza viruses were pandemic 2009 H1N1, Influenza A (other than H1N1), and Influenza B. The test was systematically carried out starting April 2015.

2.2. Statistical analysis

Statistical analysis was done using Excel and descriptive analyses were done for demographic, results of the tests and the monthly number of cases. Minitab® (Minitab Inc. Version 17, PA16801, USA; 2017) was used to calculate the mean age (\pm SD) of patients with influenza.

3. Results

During the study period from 2013 to 2016, a total of 2657 patients were screened for MERS-CoV and only 20 (0.74%) tested positive. During the first two years (April 2013–March 2015), a total of 1013 patients were screened for MERS-CoV. Only 1.8% of them were positive for MERS-CoV (Table 1) and unfortunately these were not systematically screened for influenza. There was an increased number of tests in November 2015–March 2016 (Fig. 1).

From April 2015 to December 2016, a total of 1644 patients were tested for both MERS-CoV and influenza. None of the patients tested positive for MERS-CoV and 271 (16.4%) were positive for influenza. The detected influenza viruses were Influenza A (107, 6.5%), pandemic 2009 H1N1 ($n = 120$, 7.3%), and Influenza B ($n = 44$, 2.7%) (Table 1 and Fig. 2). It is interesting to note the pattern of the influenza in 2015 and 2016 (Fig. 3). Pandemic H1N1 was the most common influenza in 2015 and influenza A other than H1N1 was more common in 2016. The 2015 influenza season peaked October to December and the 2016 season had a peak in August and then October to December (Fig. 3). There was a significant difference in the mean age (\pm SD; 95% CI) of patients with H1N1 and other influenza (Fig. 4). The mean age (\pm SD; 95% CI) was 45.09 (\pm 24.32; 40.85, 49.33) for H1N1, 63.70 (\pm 20.34; 59.21, 68.19) for influenza A, 55.11 (\pm 25.27; 48.11, 62.12) for Influenza B, and 61.28 (\pm 23.82; 60.03, 62.54) for influenza negative patients ($P < 0.0001$).

Table 1
Number of positive tests for influenza and MERS-CoV in relation to the study period.

Study Period	MERS-CoV	Influenza A	H1N1	Influenza B	Grand Total
4/2013–3/2015	20 (1.8)	ND	ND	ND	1092
4/2015–12/2016	0 (0)	107 (6.5)	120 (7.2)	44 (2.6)	1644
Overall	20 (0.74)				2736

4. Discussion

In this study, we presented the surveillance data on MERS-CoV over a four year period and the surveillance for influenza over a two year period. MERS-CoV was only detected in 20 (0.75%) from a total of 2657 patients as detailed in previous publication [22,24]. The earliest surveillance study from Saudi Arabia was done from 1 October 2012 to 30 September 2013 and tested a total of 5065 samples [21]. In that study, the MERS positivity rate was 2% [21]. A second surveillance of MERS-CoV in Saudi Arabia was conducted from April 1, 2015 to February 1, 2016 and included a total of 57,363 suspected MERS cases [25]. The study showed only 384 (0.7%) MERS-CoV positive cases [25]. In a study in the United States, two (0.4%) imported cases were detected among 490 patients-under investigation in 2013–2014 [26]. In a surveillance study of 1586 unique persons from the United Arab Emirates between January 1, 2013 and April 17, 2014, 41 (3%) tested positive for MERS-CoV infection [27]. In the South Korea outbreak, 184 (1%) had MERS among 16,752 suspected cases [28]. In a small study from Saudi Arabia, MERS-CoV was not detected in 182 cases tested November 2013 and January 2014 (winter time) [29]. Thus, the overall positivity of MERS-CoV among a large cohort remains low. There is a need for a better tool to identify patients with high probability of MERS-CoV. However, a case control study and a large cohort study did not reveal significant predictor of MERS-CoV infection [22,30].

The monthly frequency of suspected MERS cases that were tested showed variation with an apparent increase in the tested number during November 2015–March 2016. This apparent increase likely represented an increased activity of influenza during that time. There was no relation to the Hajj season as it occurred during September 21–26, 2015 (Fig. 1). In addition at that time, there were no known outbreaks in the Kingdom of Saudi Arabia to account for such an increase in the testing. The 2015 outbreaks occurred in Al-Hasa in May 2015 [31] and in Riyadh in August 2015 [7,32,33]. Previous studies had shown increased testing of patients for MERS-CoV during outbreaks [4]. In the current study, the 2015 season was predominated by 2009 pandemic H1N1 whereas influenza A was more common during 2016. Similarly, in the United States the 2014–2015 season was predominated by pandemic H1N1 and H3N2 was more common during the 2016–2017 season [34,35]. We found that influenza rather than MERS-CoV was more common among the tested patients. The findings are also consistent with other studies among travelers and pilgrims where influenza far exceeded MERS [36–40]. Similarly, in a small study in Saudi Arabia, influenza viruses were detected in 16% of 182 patients [29]. Similarly, among a small study of 52 suspected MERS cases in the United States of America, Influenza was the most commonly (35%) identified respiratory agent [41] and another study found influenza A and B in 11% of 296 investigated patients [26]. Thus, it is important to test for common respiratory pathogens such as influenza viruses and it should be noted that identification of a respiratory pathogen should not exclude MERS-CoV testing [42]. One report indicated co-infection with influenza and MERS in four patients [43]. However, epidemiologic differences between different countries should remain as an important predictor of the existence of MERS-CoV infection.

The mean age of patients with H1N1 was younger than the other influenza patients of at least 10 years (45.09 vs. 63.70 for influenza A, 55.11 for Influenza B, and 61.28 for influenza negative patients ($P < 0.0001$). The initial cases of pandemic 2009 H1N1 were also younger than the influenza negative patients [44]. In a small study of 196 patients, influenza B patients were younger than other influenza [45] and in another study the mean age was lower for patients with influenza B (16.4 yr) than (H1N1) pdm09 influenza infection. However, these studies included children and thus are not comparable with the present study [46].

Similar results were obtained in travelers returning from the Middle East. These studies showed the lack of MERS-CoV among travelers and that influenza was more common among French travelers [47,48],




Fig. 1. Monthly number of patients who were tested for MERS-CoV and the time of occurrence of major outbreaks.




Fig. 2. Monthly influenza type from April 2015 to December 2016.




Fig. 3. A Line graph showing the monthly number of isolated influenza by type.




Fig. 4. Interval plot of age and 95% confidence interval of age among influenza patients.

Austrian returning pilgrims [40], British travelers [49], German travelers [50], and travelers to California, United States [41]. The presence of influenza infection among those travelers stress the need for influenza vaccination in travelers, notably for those going for the Hajj and Umrah in Saudi Arabia.

In conclusion, MERS-CoV was a rare cause of community acquired pneumonia (CAP) and other viral causes including influenza are much more common. The epidemiology of influenza mirrored the epidemiology of influenza worldwide. The study highlights the importance of the surveillance system to elucidate the epidemiology of respiratory infections in order to formulate appropriate control measures. Inter-hospital and intra-hospital transmission of MERS-CoV infection is an important element of the transmission of this virus and it is imperative to continue to have early recognition of cases and constant application of infection control measures to abort the hospital transmissions of the virus [18,19].

Conflict of interest

All authors have no conflict of interest to declare.

Financial support

All authors have no funding.

References

- [1] Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med* 2012;367:1814–20. <http://dx.doi.org/10.1056/NEJMoa1211721>.
- [2] Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DAT, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. *N Engl J Med* 2013;369:407–16. <http://dx.doi.org/10.1056/NEJMoa1306742>.
- [3] Oboho IK, Tomczyk SM, Al-Asmari AM, Banjar AA, Al-Mugti H, Aloraini MS, et al. 2014 MERS-CoV outbreak in Jeddah—a link to health care facilities. *N Engl J Med* 2015;372:846–54. <http://dx.doi.org/10.1056/NEJMoa1408636>.
- [4] Drosten C, Muth D, Corman VM, Hussain R, Al Masri M, HajOmar W, et al. An observational, laboratory-based study of outbreaks of middle East respiratory syndrome coronavirus in Jeddah and Riyadh, kingdom of Saudi Arabia, 2014. *Clin Infect Dis* 2015;60:369–77. <http://dx.doi.org/10.1093/cid/ciu812>.
- [5] Fagbo SF, Skakni L, Chu DKW, Garbati MA, Joseph M, Peiris M, et al. Molecular epidemiology of hospital outbreak of Middle East respiratory syndrome, Riyadh, Saudi Arabia, 2014. *Emerg Infect Dis* 2015;21:1981–8. <http://dx.doi.org/10.3201/eid2111.150944>.
- [6] Almekhlafi GA, Albarrak MM, Mandourah Y, Hassan S, Alwan A, Abudayah A, et al. Presentation and outcome of Middle East respiratory syndrome in Saudi intensive care unit patients. *Crit Care* 2016;20:123. <http://dx.doi.org/10.1186/s13054-016-1303-8>.
- [7] Balkhy HH, Alenazi TH, Alshamrani MM, Baffoe-Bonnie H, Al-Abdely HM, El-Saed A, et al. Notes from the field: nosocomial outbreak of Middle East respiratory syndrome in a large tertiary care hospital—Riyadh, Saudi Arabia, 2015. *MMWR Morb Mortal Wkly Rep* 2016;65:163–4. <http://dx.doi.org/10.15585/mmwr.mm6506a5>.
- [8] Al-Tawfiq JA, Memish ZA. Drivers of MERS-CoV transmission: what do we know? *Expert Rev Respir Med* 2016;10:331–8. <http://dx.doi.org/10.1586/17476348.2016.1150784>.
- [9] Hijawi B, Abdallat M, Sayaydeh A, Alqasrawi S, Haddadin A, Jaarour N, et al. Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation. *East Mediterr Heal J* 2013;19(Suppl 1):S12–8.
- [10] Kim Y, Lee S, Chu C, Choe S, Hong S, Shin Y. The characteristics of middle eastern respiratory syndrome coronavirus transmission dynamics in South Korea. *Osong Public Heal Res Perspect* 2016;7:49–55. <http://dx.doi.org/10.1016/j.phrp.2016.01.001>.
- [11] Cowling BJ, Park M, Fang VJ, Wu P, Leung GM, Wu JT. Preliminary epidemiologic assessment of MERS-CoV outbreak in South Korea, May–June 2015. *Euro Surveill* 2015;20.
- [12] World Health Organization (WHO). Middle East respiratory syndrome coronavirus (MERS-CoV). WHO; 2017 Available at: <http://www.who.int/emergencies/mers-cov/en/>, Accessed date: 1 May 2017.
- [13] Memish Z a, Zumla AI, Al-Hakeem RF, Al-Rabeeah A a, Stephens GM. Family cluster of Middle East respiratory syndrome coronavirus infections. *N Engl J Med* 2013;368:2487–94. <http://dx.doi.org/10.1056/NEJMoa1303729>.
- [14] Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. *Lancet Infect Dis* 2013;13:752–61. [http://dx.doi.org/10.1016/S1473-3099\(13\)70204-4](http://dx.doi.org/10.1016/S1473-3099(13)70204-4).
- [15] Albarrak AM, Stephens GM, Hewson R, Memish ZA. Recovery from severe novel coronavirus infection. *Saudi Med J* 2012;33:1265–9.
- [16] Saudi Ministry of Health C and CC. MERS-CoV Statistics n.d. <http://www.moh.gov.sa/en/ccc/pressreleases/pages/default.aspx>.
- [17] Al-Abdallat MM, Payne DC, Alqasrawi S, Rha B, Tohme RA, Abedi GR, et al. Hospital-Associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. *Clin Infect Dis* 2014;59:1225–33. <http://dx.doi.org/10.1093/cid/ciu359>.
- [18] Al-Tawfiq JA, Perl TM. Middle East respiratory syndrome coronavirus in healthcare settings. *Curr Opin Infect Dis* 2015;28:392–6. <http://dx.doi.org/10.1097/QCO.000000000000178>.
- [19] Memish ZA, Al-Tawfiq JA. Middle East respiratory syndrome coronavirus infection control: the missing piece? *Am J Infect Control* 2014;42. <http://dx.doi.org/10.1016/j.ajic.2014.06.019>.
- [20] Al-Tawfiq JA, Zumla A, Gautret P, Gray GC, Hui DS, Al-Rabeeah AA, et al. Surveillance for emerging respiratory viruses. *Lancet Infect Dis* 2014;14. [http://dx.doi.org/10.1016/S1473-3099\(14\)70840-0](http://dx.doi.org/10.1016/S1473-3099(14)70840-0).
- [21] Memish ZA, Al-Tawfiq JA, Makhdoom HQ, Al-Rabeeah AA, Assiri A, Alhakeem RF, et al. Screening for Middle East respiratory syndrome coronavirus infection in hospital patients and their healthcare worker and family contacts: a prospective descriptive study. *Clin Microbiol Infect* 2014;20:469–74. <http://dx.doi.org/10.1111/1469-0691.12562>.
- [22] Al-Tawfiq JA, Hinedi K, Ghandour J, Khairalla H, Musleh S, Ujayli A, et al. Middle East Respiratory Syndrome-Coronavirus (MERS-CoV): a case-control study of hospitalized patients. *Clin Infect Dis* 2014;59:160–5. <http://dx.doi.org/10.1093/cid/ciu226>.
- [23] Corman VM, Müller MA, Costabel U, Timm J, Binger T, Meyer B, et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. *Euro*

- Surveill 2012;17:49.
- [24] Al-Tawfiq JA, Hinedi K, Abbasi S, Babiker M, Sunji A, Eltigani M. Hematologic, hepatic, and renal function changes in hospitalized patients with Middle East respiratory syndrome coronavirus. *Int J Lab Hematol* 2017;39:272–8. <http://dx.doi.org/10.1111/ijlh.12620>.
- [25] Bin Saeed AA, Abedi GR, Alzahrani AG, Salemeah I, Abdirizak F, Alhakeem R, et al. Surveillance and testing for Middle East respiratory syndrome coronavirus, Saudi Arabia, April 2015–february 2016. *Emerg Infect Dis* 2017;23:682–5. <http://dx.doi.org/10.3201/eid2304.161793>.
- [26] Schneider E, Chommanard C, Rudd J, Whitaker B, Lowe L, Gerber SI. Evaluation of patients under investigation for MERS-CoV infection, United States, January 2013–October 2014. *Emerg Infect Dis* 2015;21:1220–3. <http://dx.doi.org/10.3201/eid2107.141888>.
- [27] Al Hosani FI, Pringle K, Al Mulla M, Kim L, Pham H, Alami NN, et al. Response to emergence of Middle East respiratory syndrome coronavirus, Abu Dhabi, United Arab Emirates, 2013–2014. *Emerg Infect Dis* 2016;22:1162–8. <http://dx.doi.org/10.3201/eid2207.160040>.
- [28] Kim KH, Tandil TE, Choi JW, Moon JM, Kim MS. Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and public health implications. *J Hosp Infect* 2017;95:207–13. <http://dx.doi.org/10.1016/j.jhin.2016.10.008>.
- [29] Abdulhaq AA, Basode VK, Hashem AM, Alsharri AS, Badroon NA, Hassan AM, et al. Patterns of human respiratory viruses and lack of MERS-coronavirus in patients with acute upper respiratory tract infections in southwestern province of Saudi Arabia. *Adv Virol* 2017;2017:4247853. <http://dx.doi.org/10.1155/2017/4247853>.
- [30] Mohd HA, Memish ZA, Alfaraj SH, McClish D, Altuwaijri T, Alanazi MS, et al. Predictors of MERS-CoV infection: a large case control study of patients presenting with ILI at a MERS-CoV referral hospital in Saudi Arabia. *Travel Med Infect Dis* 2016;14:464–70. <http://dx.doi.org/10.1016/j.tmaid.2016.09.008>.
- [31] El Bushra HE, Abdalla MN, Al Arbash H, Alshayeb Z, Al-Ali S, Latif ZA-A, et al. An outbreak of Middle East Respiratory Syndrome (MERS) due to coronavirus in Al-Ahssa Region, Saudi Arabia, 2015. *East Mediterr Health J* 2016;22:468–75.
- [32] Balkhy HH, Alenazi TH, Alshamrani MM, Baffoe-Bonnie H, Arabi Y, Hijazi R, et al. Description of a hospital outbreak of Middle East respiratory syndrome in a large tertiary care hospital in Saudi Arabia. *Infect Control Hosp Epidemiol* 2016;37:1147–55. <http://dx.doi.org/10.1017/ice.2016.132>.
- [33] Al-Dorzi HM, Aldawood AS, Khan R, Baharoon S, Alchin JD, Matroud AA, et al. The critical care response to a hospital outbreak of Middle East respiratory syndrome coronavirus (MERS-CoV) infection: an observational study. *Ann Intensive Care* 2016;6:101. <http://dx.doi.org/10.1186/s13613-016-0203-z>.
- [34] Davlin SL, Blanton L, Kniss K, Mustaqim D, Smith S, Kramer N, et al. Influenza activity - United States, 2015–16 season and composition of the 2016–17 influenza vaccine. *MMWR Morb Mortal Wkly Rep* 2016;65:567–75. <http://dx.doi.org/10.15585/mmwr.mm6522a3>.
- [35] CDC. 2016–2017 Influenza Season n.d. https://www.cdc.gov/flu/weekly/pdf/External_F1716.pdf (accessed April 30, 2017).
- [36] Refaey S, Amin MM, Roguski K, Azziz-Baumgartner E, Uyeki TM, Labib M, et al. Cross-Sectional survey and surveillance for influenza viruses and MERS-CoV among Egyptian pilgrims returning from Hajj during 2012–2015. *Influenza Other Respi Viruses* 2016. <http://dx.doi.org/10.1111/irv.12429>.
- [37] Atabani SF, Wilson S, Overton-Lewis C, Workman J, Kidd IM, Petersen E, et al. Active screening and surveillance in the United Kingdom for Middle East respiratory syndrome coronavirus in returning travellers and pilgrims from the Middle East: a prospective descriptive study for the period 2013–2015. *Int J Infect Dis* 2016;47:10–4. <http://dx.doi.org/10.1016/j.ijid.2016.04.016>.
- [38] Koul PA, Mir H, Saha S, Chadha MS, Potdar V, Widdowson M-A, et al. Influenza not MERS CoV among returning Hajj and Umrah pilgrims with respiratory illness, Kashmir, north India, 2014–15. *Travel Med Infect Dis* 2017;15:45–7. <http://dx.doi.org/10.1016/j.tmaid.2016.12.002>.
- [39] Gautret P, Benkouiten S, Al-Tawfiq JA, Memish ZA. Hajj-associated viral respiratory infections: a systematic review. *Travel Med Infect Dis* 2016;14:92–109. <http://dx.doi.org/10.1016/j.tmaid.2015.12.008>.
- [40] Aberle JH, Popow-Kraupp T, Kreidl P, Laferl H, Heinz FX, Aberle SW. Influenza A and B viruses but not MERS-CoV in Hajj pilgrims, Austria, 2014. *Emerg Infect Dis* 2015;21:726–7. <http://dx.doi.org/10.3201/eid2104.141745>.
- [41] Shahkarami M, Yen C, Glaser C, Xia D, Watt J, Wadford DA. Laboratory testing for Middle East respiratory syndrome coronavirus, California, USA, 2013–2014. *Emerg Infect Dis* 2015;21:1664–6. <http://dx.doi.org/10.3201/eid2109.150476>.
- [42] CDC. Interim Guidelines for Clinical Specimens from PUI | CDC n.d. <https://www.cdc.gov/coronavirus/mers/guidelines-clinical-specimens.html> (accessed May 7, 2017).
- [43] Alfaraj SH, Al-Tawfiq JA, Alzahrani NA, Altwaijri TA, Memish ZA. The impact of co-infection of influenza A virus on the severity of Middle East Respiratory Syndrome Coronavirus. *J Infect* 2017. <http://dx.doi.org/10.1016/j.jinf.2017.02.001>.
- [44] Al-Tawfiq JA, Abed M, Saadeh BM, Ghandour J, Shaltaf M, Babiker MM. Pandemic influenza A (2009 H1N1) in hospitalized patients in a Saudi Arabian hospital: epidemiology and clinical comparison with H1N1-negative patients. *J Infect Public Health* 2011;4. <http://dx.doi.org/10.1016/j.jiph.2011.09.005>.
- [45] Kaji M, Watanabe A, Aizawa H. Differences in clinical features between influenza A H1N1, A H3N2, and B in adult patients. *Respirology* 2003;8:231–3.
- [46] Purakayastha DR, Gupta V, Broor S, Sullender W, Fowler K, Widdowson M-A, et al. Clinical differences between influenza A (H1N1) pdm09 & influenza B infections identified through active community surveillance in North India. *Indian J Med Res* 2013;138:962–8.
- [47] Gautret P, Charrel R, Benkouiten S, Belhouchat K, Nougairede A, Drali T, et al. Lack of MERS coronavirus but prevalence of influenza virus in French pilgrims after 2013 Hajj. *Emerg Infect Dis* 2014;20:728–30. <http://dx.doi.org/10.3201/eid2004.131708>.
- [48] Griffiths K, Charrel R, Lagier J-C, Nougairede A, Simon F, Parola P, et al. Infections in symptomatic travelers returning from the Arabian peninsula to France: a retrospective cross-sectional study. *Travel Med Infect Dis* 2016;14:414–6. <http://dx.doi.org/10.1016/j.tmaid.2016.05.002>.
- [49] Thomas HL, Zhao H, Green HK, Boddington NL, Carvalho CFA, Osman HK, et al. Enhanced MERS coronavirus surveillance of travelers from the Middle East to England. *Emerg Infect Dis* 2014;20:1562–4. <http://dx.doi.org/10.3201/eid2009.140817>.
- [50] German M, Olsha R, Kristjanson E, Marchand-Austin A, Peci A, Winter A-L, et al. Acute respiratory infections in travelers returning from MERS-CoV-affected areas. *Emerg Infect Dis* 2015;21:1654–6. <http://dx.doi.org/10.3201/eid2109.150472>.